ACX recreates synthetic compounds that bacteria uses to kill microbes for therapeutic development.
ACX has raised $500K in total funding. The most recent round was Pre-Seed. The last funding was announced in September 2024.
ACX's investors include Y Combinator.
ACX is headquartered in San Francisco, United States.
ACX recreates synthetic compounds that bacteria uses to kill microbes for therapeutic development.
ACX is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ACX — Funding & Investors." VCBacked, September 25, 2024, https://www.vcbacked.co/company/acx-san-francisco. Accessed July 27, 2026.
VCBacked. (2024). ACX — Funding & Investors. Retrieved July 27, 2026, from https://www.vcbacked.co/company/acx-san-francisco
{{cite web |title=ACX — Funding & Investors |url=https://www.vcbacked.co/company/acx-san-francisco |website=VCBacked |access-date=July 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated